News & Updates

Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.

Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.

Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.